MARKET

TVTX

TVTX

Travere Therapeutics Inc
NASDAQ
50.65
-0.91
-1.76%
After Hours: 50.65 0 0.00% 19:30 11/13 EST
OPEN
51.08
PREV CLOSE
51.56
HIGH
51.54
LOW
49.20
VOLUME
708.20K
TURNOVER
--
52 WEEK HIGH
68.73
52 WEEK LOW
22.59
MARKET CAP
4.86B
P/E (TTM)
-38.9915
1D
5D
1M
3M
1Y
5Y
1D
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 2d ago
Weekly Report: what happened at TVTX last week (1102-1106)?
Weekly Report · 5d ago
Travere Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 11/07 03:11
Travere Therapeutics Price Target Cut to $86.00/Share From $90.00 by JP Morgan
Dow Jones · 11/07 03:11
Travere Therapeutics (TVTX) Receives a Buy from J.P. Morgan
TipRanks · 11/06 14:58
Travere Therapeutics price target lowered to $86 from $90 at JPMorgan
TipRanks · 11/06 12:58
Travere Therapeutics Price Target Cut to $67.00/Share From $78.00 by Leerink Partners
Dow Jones · 11/05 21:26
Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67
Benzinga · 11/05 21:16
More
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Webull offers Travere Therapeutics Inc stock information, including NASDAQ: TVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVTX stock methods without spending real money on the virtual paper trading platform.